I am the Managing Director of Erchonia Lasers Ltd, leading the distribution for Erchonia Corp across Europe, the Middle East, Africa, and India. We specialise in cutting-edge, clinically validated Non-thermal Laser technologies. Our portfolio includes:- **Emerald Laser**: The first FDA cleared non-invasive green laser for body contouring and cellulite removal, suitable for patients up to a 40 BMI. Emerald has revolutionised aesthetic treatments, providing a non-surgical liposuction alternative with significant results in double-blind, randomized studies, achieving an average 15cm circumferential loss from the abdomen, waist, and hips on patients who met the study criteria.- **Pain Management Lasers**: Our range of handheld and unmanned lasers are FDA cleared for various conditions including neck and shoulder pain, nociceptive mask pain, chronic plantar fasciitis, and chronic lower back pain. These devices leverage a precise photochemical reaction at the cellular level to deliver effective clinical results, changing cellular memory, muscular memory and increasing circulation.- **Lunula Laser**: This advanced treatment for onychomycosis employs patented rotating 635nm and 405nm laser beams to safely and painlessly eliminate toe fungus by disrupting its immune defense, thereby enhancing oxygen levels and blood circulation. This facilitates healthy nail growth, as evidenced by an independent one-year study in Ireland by the respected Podiatrist/Podiatric Surgeon, Mr. Robert Sullivan, which showed a 90% clearance and 98% improvement rate. Data from this study helped Lunula secure its FDA clearance.Our commitment to advancing non-invasive medical solutions is unwavering, as we continue to set industry standards for safety and effectiveness in laser therapy. Connect with me to explore how our innovative technologies can enhance your practice and patient care.

I previously managed the UK sales and operational network for a distributor of Erchonia Corp, a leader in low-level laser therapy. Our portfolio featured advanced, clinically proven non-thermal laser technologies that were FDA cleared for non-invasive body contouring, cellulite removal, and promoting clear nail growth in conditions like onychomycosis. Unlike traditional lasers that use photo-thermal mechanisms, our cold lasers achieved clinical results through a photo-chemical process, setting them apart in the field of medical aesthetics and therapeutic treatments.

I spearheaded the launch of direct business operations in the UK, focusing on defining and promoting a range of laser and radio frequency aesthetic modalities. My responsibilities included:- Establishing an extended UK sales team and office, collaborating closely with the Managing Director of EMEA to foster international growth.- Developing a more robust sales and operational framework to enable sustained business expansion.- Cultivating ongoing partnerships with key opinion leaders in Cosmetic Medicine, Dermatology, and Plastic Surgery to ensure high satisfaction with our products and services.**Reason for Leaving:** A shift in strategic direction required relocating the role to mainland Europe, which was not feasible for me at the time.

I managed the deployment of widefield retinal imaging devices across the UK, serving Optometrists and Ophthalmologists, and was at the forefront of introducing the company's new global sales objectives into the UK Optic market. My role involved:- Leading a UK sales team focused on new business growth and enhanced asset utilization.- Developing and enforcing a cohesive UK infrastructure to promote sustainable growth and enhance customer support.- Engaging extensively with key opinion leaders and forging national account alliances.- Overseeing significant projects, including Diabetic Screening programs, NHS procurement partnerships, university device placements, and customer training programs.- Preparing comprehensive company reports, annual sales forecasts, and strategic business plans.- Achieving an unprecedented 1000% growth in new business placements in the fiscal year 2009/2010.**Reason for Leaving:** I transitioned to Solta Medical, drawn by opportunities that aligned more closely with my passion for roles encompassing both UK and international responsibilities, particularly in medical aesthetics.

ASIC, established in the US, served as a parent company to international subsidiaries, including the UK-based R & B Aesthetic Solutions. R & B secured multi-market distribution rights for Atlean BTCP, an injectable facial volumizer composed of Tri-Calcium Phosphate and Hyaluronic Acid. Key highlights of my role included:- Spearheading a global initiative to develop and deliver cutting-edge medical aesthetic technologies to the UK and international markets.- Successfully acquiring the distribution contract to launch Atlean BTCP in the UK and various other international markets.- Leading a dedicated team of Sales Executives and Aesthetic Trainers, along with managing international distributors.- Developing and presenting a compelling global business vision to secure investment for ASIC.- Researching and identifying emerging technologies and potential international distribution opportunities.- Engaging in strategic planning and negotiations for potential acquisitions and mergers.Regrettably, the project faced financial hurdles due to the closure of specific US banking institutions and downturns in the US stock markets, leading to the withdrawal of investment. Furthermore, the distribution agreement for Atlean BTCP concluded after Stiefel Laboratories acquired the patent and opted for direct market distribution.

As the National Sales Manager for a leading UK distributor in plastic surgery and aesthetic products, I spearheaded all sales and marketing initiatives and played a pivotal role in strategic company decisions. Our product range included breast implants, liposuction equipment, plastic surgery instruments, endoscopic devices, and non-surgical dermal fillers. My key responsibilities encompassed:- Leading and expanding a team of Sales Agents and Trainers, focusing on maximizing their potential and boosting performance through dedicated mentoring and training.- Cultivating strong, ongoing relationships with key stakeholders including Plastic Surgeons, NHS/PCT purchasing teams, and Private Hospital Groups.- Contributing insights into new product technology, application, and compliance.- Playing a crucial role in the successful launch of the injectable dermal filler, Evolence (Porcine Collagen), which significantly increased sales.- Leading the introduction of a new line of disposable products, including specialized plastic surgery instruments, liposuction cannulae, and fat transfer kits, enhancing our market offerings and customer satisfaction.

I held a senior sales position focused on delivering high-value diagnostic imaging services (MRI/CT/PET CT) to both NHS and private hospitals. My primary role involved engaging with Orthopaedic Surgeons, Neurosurgeons, Radiologists at NHS and private hospitals, as well as Finance Directors and Heads of Commissioning at NHS hospitals and Primary Care Trusts. A key part of my role was co-organizing Spinal and Limb Symposiums alongside local Orthopaedic Surgeons, Neurosurgeons, and Radiologists. These events were instrumental in raising awareness about various surgical techniques and the critical role of MRI and CT scans in the diagnostic process.